Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: Clopidogrel/Tegoprazan - Daehwa Pharmaceutical; DHP-2302; DHP-2302R1/DHP-2302R2; DHP-2302R2/DHP-2302R1

Latest Information Update: 29 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Daehwa Pharmaceutical
  • Class 2 ring heterocyclic compounds; Amides; Anti-inflammatories; Anti-ischaemics; Antibacterials; Antihaemorrhagics; Antiplatelets; Antithrombotics; Antiulcers; Benzimidazoles; Benzopyrans; Cardiovascular therapies; Chlorobenzenes; Esters; Fluorobenzenes; Ischaemic heart disorder therapies; Pyridines; Thienopyridines; Vascular disorder therapies
  • Mechanism of Action H(+) K(+)-exchanging ATPase inhibitors; Platelet ADP receptor antagonists; Platelet aggregation inhibitors; Potassium-competitive acid blockers; Purinergic P2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Gastrointestinal haemorrhage

Most Recent Events

  • 27 Mar 2024 Daehwa Pharmaceutical plans phase III clinical trial
  • 04 Mar 2024 Phase-I clinical trials in Gastrointestinal haemorrhage in South Africa (PO) (NCT06318845)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top